Document Detail

Prolonged postoperative venous thrombo-embolism prophylaxis is cost-effective in advanced ovarian cancer patients.
MedLine Citation:
PMID:  22940486     Owner:  NLM     Status:  Publisher    
OBJECTIVE: The purpose of this study was to investigate the cost-effectiveness of prolonged prophylaxis with enoxaparin in high-risk surgical patients with ovarian cancer. In addition, we sought to quantify the impact of prolonged prophylaxis (PP) on the incidence of venous thromboembolism (VTE), its related complications, and overall patient survival. METHODS: A Markov decision analytic model was used to estimate the costs, resource allocation and outcomes associated with the prolonged use of enoxaparin, for a total of four weeks after surgery, in patients undergoing primary debulking surgery for stage IIIC ovarian cancer. We estimated incremental cost per quality-adjusted life-year (QALY) at one and five year intervals; the estimated reduction in VTE episodes, bleeding episodes, and survival at the five year interval for a simulated cohort of 10,000 women. RESULTS: The incremental cost effectiveness ratio (ICER) for prolonged prophylaxis (PP) was $5236/QALY and $-1462/QALY at one and five years respectively. For patients receiving PP, the model estimated a 12% reduction in the clinically evident VTE episodes and a higher five-year survival (31.61% vs. 29.96%; p<0.0001). Resource allocation analysis reveals that 95% of initial investment cost of prolonged enoxaparin is recovered within one year. CONCLUSIONS: In ovarian cancer patients undergoing open abdominal surgery, prolonged VTE prophylaxis not only improves patient outcomes, but is also a cost saving strategy when modeled over five years. A significant reduction in the episodes of VTE and a higher overall survival warrants consideration for the routine use of PP in this patient population.
Shitanshu Uppal; Enrique Hernandez; Moushumi Dutta; Vani Dandolu; Stephen Rose; Ellen Hartenbach
Related Documents :
1733356 - Early surgical débridement of symptomatic pancreatic necrosis is beneficial irrespecti...
14993026 - Is reporting of recurrence data important in pancreatic cancer?
7505106 - Flushable exo-endodrainage: a modified palliative approach to non-resectable malignant ...
24645966 - Efficacy and tolerability of low-volume (2 l) versus single- (4 l) versus split-dos...
15807826 - Effect of mitomycin c on ciliary body and intraocular pressure with various application...
3342586 - Shoulder hemiarthroplasty at ucla.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-8-29
Journal Detail:
Title:  Gynecologic oncology     Volume:  -     ISSN:  1095-6859     ISO Abbreviation:  Gynecol. Oncol.     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-9-3     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0365304     Medline TA:  Gynecol Oncol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 Elsevier Inc. All rights reserved.
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Wisconsin, Madison.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The formation of reactive species having hydroxyl radical-like reactivity from UV photolysis of N-ni...
Next Document:  Histopathologic differences account for racial disparity in uterine cancer survival.